Hua Medicine
IPOGlobal innovation in diabetes care.
Public · Shanghai, China · Founded 2010 · $212.5M raised
- Headquarters
- Shanghai
- Employees
- 51–200
- Founded
- 2010
- Business Model
- B2B
- Website
- huamedicine.com
- Total Funding
- $212.5M
- Last Round
- $117.4M Series DMar 2018
- Rounds
- 4
- Type
- Public
About
Hua Medicine is a clinical-stage biotech company focused on innovative therapies for type 2 diabetes and CNS disorders. Its lead product, HuaTangNing (dorzagliatin), a first-in-class glucokinase activator, was approved in China in 2022 for T2D patients, including those with renal impairment.
Summary
Hua Medicine is a Biotech company based in Shanghai, China, founded in 2010. It has raised $212.5M in total across 4 rounds, most recently a $117.4M Series D round in Mar 2018. Investors include ARCH Venture Partners, Venrock and Blue Pool Capital.
Funding History
Sep 2018
Sign up to see all 5 rounds
Series A through IPO — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/hua-medicine"><img src="https://indexed.vc/api/badge/company/hua-medicine" alt="Hua Medicine on Indexed.vc" width="260" height="76" /></a>